Bookmark
Forward
QuickView for Mepenzolate (compound)
DrugBank
Identification
| Name: | mepenzolate |
|---|---|
| Name (isomeric): | DB04843 |
| Drug Type: | small molecule |
| Synonyms: |
N-Methyl-3-piperidyldiphenylglycolate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; Mepenzolic acid; Mepenzolate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide
|
| Brand: | Gastropidil, Tralanta, Cantil, Cantilon, Colopiril, Eftoron, Cantril, Colibantil, Mepenzolon, Delevil, Trancolon, Cantilaque, Colum |
| Category: | Parasympatholytics, Anticholinergic Agents |
| CAS number: | 25990-43-6 |
Pharmacology
| Indication: | For use as adjunctive therapy in the treatment of peptic ulcer. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. |
|---|---|
| Pharmacology: | Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. |
| Mechanism of Action: | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It specifically antagonizes muscarinic receptors. This leads to decreases in gastric acid and pepsin secretion and suppression of spontaneous contractions of the colon. |
| Absorption: | Between 3 and 22% of an orally administered dose is excreted in the urine over a 5-day period, with the majority of the radioactivity appearing on Day 1. The remainder appears in the next 5 days in the feces and presumably has not been absorbed. |
| Route of elimination: | Between 3 and 22% of an orally administered dose is excreted in the urine over a 5-day period, with the majority of the radioactivity appearing on Day 1. |
| Toxicity: | The signs and symptoms of overdosage are headache; nausea; vomiting; blurred vision; dilated pupils; hot, dry skin; dizziness; dryness of the mouth; difficulty in swallowing; and CNS stimulation. A curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis). The oral LD50 is greater than 750 mg/kg in mice and greater than 1000 mg/kg in rats. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
